Temsirolimus

Drug Profile

Temsirolimus

Alternative Names: CCI-779; Cell cycle inhibitor-779; NSC-683864; Torisel

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Developer Johann Wolfgang Goethe Universitatsklinikum; Multiple Myeloma Research Consortium; NCIC Clinical Trials Group; Pfizer; Wyeth
  • Class Antineoplastics; Macrolides
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma; Mantle-cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Mantle-cell lymphoma; Renal cell carcinoma
  • Phase II Acute myeloid leukaemia; Bladder cancer; Glioblastoma; Glioma; Hodgkin's disease; Non-Hodgkin's lymphoma
  • Phase I/II Follicular lymphoma; Head and neck cancer
  • Phase I Acute lymphoblastic leukaemia; Lymphoma; Solid tumours
  • No development reported Colorectal cancer; Multiple myeloma; Prostate cancer
  • Discontinued Breast cancer; Pancreatic cancer; Soft tissue sarcoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Colorectal-cancer in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Glioblastoma(Combination therapy, Metastatic disease) in Germany (IV, Infusion)
  • 19 Sep 2017 Johannes Gutenberg University Mainz and Pfizer completes a phase I/II trial in Follicular lymphoma or Mantle cell lymphoma in Germany (NCT01078142)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top